(Q41932446)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28935918%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference

22 August 2022

Host-directed therapies for bacterial and viral infections (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28935918%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28935918%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

3

Richard S Hotchkiss

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28935918%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

author name string

Stefan H E Kaufmann

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28935918%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Anca Dorhoi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28935918%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

publication date

22 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28935918%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

30 March 2020

1 January 2018

1 reference

22 August 2022

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28935918%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

22 August 2022

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28935918%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28935918%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

page(s)

35-56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28935918%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd.2017.162

30 March 2020

exact match

0 references

cites work

Approved Antiviral Drugs over the Past 50 Years

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Novel vaccination strategies against tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Progress toward active or passive HIV-1 vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

HIV entry: a game of hide-and-fuse?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

CCR5: From Natural Resistance to a New Anti-HIV Strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The role of immunophilins in viral infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-directed conformational switch in Itk.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Manipulation of the mononuclear phagocyte system by Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Autophagy in immunity and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Organelle membrane proteomics reveals differential influence of mycobacterial lipoglycans on macrophage phagosome maturation and autophagosome accumulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Effects of Mycobacterium tuberculosis ESAT-6/CFP-10 fusion protein on the autophagy function of mouse macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Thermostable hexameric form of Eis (Rv2416c) protein of M. tuberculosis plays an important role for enhanced intracellular survival within macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Mycobacterium tuberculosis eis regulates autophagy, inflammation, and cell death through redox-dependent signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Reactivation of tuberculosis during temsirolimus therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Metformin as adjunct antituberculosis therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Advancing host-directed therapy for tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Mycobacterial persistence requires the utilization of host cholesterol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Statins increase rifampin mycobactericidal effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Statin adjunctive therapy shortens the duration of TB treatment in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The application and mechanism of action of ribavirin in therapy of hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Treatment of chronic hepatitis C: current and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Guarding the frontiers: the biology of type III interferons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

AASLD guidelines for treatment of chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Aiming for cure in HBV and HDV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

HIV-1 and interferons: who's interfering with whom?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Potential efficacy of imiquimod on immunity-related cytokines in murine skin in vivo and in human Langerhans cells in vitro.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Which therapeutic strategy will achieve a cure for HIV-1?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Stem-cell-based gene therapy for HIV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Enhancing SIV-specific immunity in vivo by PD-1 blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Sharpening nature's tools for efficient tuberculosis control: A review of the potential role and development of host-directed therapies and strategies for targeted respiratory delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Phenylbutyrate Is Bacteriostatic against Mycobacterium tuberculosis and Regulates the Macrophage Response to Infection, Synergistically with 25-Hydroxy-Vitamin D3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pu

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Vitamins A & D inhibit the growth of mycobacteria in radiometric culture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Unanticipated Mycobacterium tuberculosis complex culture inhibition by immune modulators, immune suppressants, a growth enhancer, and vitamins A and D: clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

All-trans retinoic acid-triggered antimicrobial activity against Mycobacterium tuberculosis is dependent on NPC2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Retinoic acid therapy attenuates the severity of tuberculosis while altering lymphocyte and macrophage numbers and cytokine expression in rats infected with Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Randomized controlled trial of zinc and vitamin A as co-adjuvants for the treatment of pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Tuberculosis screening before anti-hepatitis C virus therapy in prisons.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

[Reactivation of tuberculosis during dual therapy with pegylated interferon and ribavirin for chronic hepatitis C].

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Immunosuppression in patients who die of sepsis and multiple organ failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Programmed death-1 receptor suppresses γ-IFN producing NKT cells in human tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Analysis of Th1, Th17 and regulatory T cells in tuberculosis case contacts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

LAG3 expression in active Mycobacterium tuberculosis infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The Tim3-galectin 9 pathway induces antibacterial activity in human macrophages infected with Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Tim-3 blocking rescue macrophage and T cell function against Mycobacterium tuberculosis infection in HIV+ patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Bone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable Mycobacterium tuberculosis that survive antibiotic treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Preclinical and Clinical Evidence of Mycobacterium tuberculosis Persistence in the Hypoxic Niche of Bone Marrow Mesenchymal Stem Cells after Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Inflammation and tuberculosis: host-directed therapies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The pathophysiology and treatment of sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Monocyte deactivation in septic patients: restoration by IFN-gamma treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Harnessing the biology of IL-7 for therapeutic application

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

IL-7 Restores Lymphocyte Functions in Septic Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Treatment of progressive multifocal leukoencephalopathy with interleukin 7.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Parallels between cancer and infectious disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Dengue pathogenesis: a disease driven by the host response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Dengue Virus Nonstructural Protein 1 Induces Vascular Leakage through Macrophage Migration Inhibitory Factor and Autophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Corticosteroids for dengue - why don't they work?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The TLR4 antagonist Eritoran protects mice from lethal influenza infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The effect of statins on influenza-like illness morbidity and mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Statin treatment and mortality: propensity score-matched analyses of 2007-2008 and 2009-2010 laboratory-confirmed influenza hospitalizations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Increased survival after gemfibrozil treatment of severe mouse influenza

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Therapeutic effect of anti-macrophage inflammatory protein 2 antibody on influenza virus-induced pneumonia in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Perspectives on host adaptation in response to Mycobacterium tuberculosis: modulation of inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Inflammatory signaling in human tuberculosis granulomas is spatially organized

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Nonclinical models for antituberculosis drug development: a landscape analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Dying to live: how the death modality of the infected macrophage affects immunity to tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Increased interleukin-1 production and monocyte suppressor cell activity associated with human tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Assessment of serum IL-1, IL-2 and IFN-γ levels in untreated pulmonary tuberculosis patients: role in pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Allele-specific induction of IL-1β expression by C/EBPβ and PU.1 contributes to increased tuberculosis susceptibility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

The role of aspirin in childhood tuberculous meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Tumor necrosis factor alpha in mycobacterial infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Adalimumab treatment of life-threatening tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Cytokine levels correlate with a radiologic score in active pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Alteration of serum inflammatory cytokines in active pulmonary tuberculosis following anti-tuberculosis drug therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Risk of tuberculosis reactivation with tofacitinib (CP-690550).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Corticosteroid effects on sputum culture in pulmonary tuberculosis: a meta-regression analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Vascular endothelial growth factor levels in active pulmonary tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Increased serum level of vascular endothelial growth factor in pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Mycobacterium tuberculosis exploits the formation of new blood vessels for its dissemination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Interception of host angiogenic signalling limits mycobacterial growth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Active tuberculosis during temsirolimus and bevacizumab treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Subcutaneous tuberculosis formation during FOLFIRI and bevacizumab treatment: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Mycobacterium tuberculosis: success through dormancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Understanding the Warburg effect: the metabolic requirements of cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Critical role of methylglyoxal and AGE in mycobacteria-induced macrophage apoptosis and activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Mycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Tuberculosis, pulmonary cavitation, and matrix metalloproteinases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Effect of matrix metalloproteinase-9 -1562C/T gene polymorphism on manifestations of pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Gender-dependent differences in plasma matrix metalloproteinase-8 elevated in pulmonary tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Reverse translation in tuberculosis: neutrophils provide clues for understanding development of active disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Antimicrobial Resistance in Mycobacterium tuberculosis: The Odd One Out.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

7 January 2021

inferred from DOI database lookup

Inhibition by retinoic acid of multiplication of virulent tubercle bacilli in cultured human macrophages.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.162

7 January 2021

inferred from DOI database lookup

Maraviroc: a review of its use in HIV infection and beyond

1 reference

12 December 2020

Immunometabolism in Tuberculosis

1 reference

12 December 2020

Infection-Induced Vascular Permeability Aids Mycobacterial Growth

1 reference

12 December 2020

Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis

1 reference

12 December 2020

Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes

1 reference

12 December 2020

Pulmonary embolism and reactivation of tuberculosis during everolimus therapy in a kidney transplant recipient

1 reference

12 December 2020

[Interferon alpha-2b in the complex therapy of patients with pulmonary tuberculosis concurrent with bronchoobstructive syndrome]

1 reference

12 December 2020

CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis

1 reference

12 December 2020

Enrichment of regulatory T-cells in blood of patients with multidrug-resistant tuberculosis.

1 reference

12 December 2020

In vitro and in vivo antimycobacterial activity of antiinflammatory drug, diclofenac sodium.

1 reference

12 December 2020

Management of external genital warts.

1 reference

12 December 2020

Imiquimod: modes of action

1 reference

12 December 2020

Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-α antibody in mice

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2017.162

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28935918%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28935918%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference